BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36215572)

  • 1.
    Subramaniam RM; DeMora L; Yao M; Yom SS; Gillison M; Caudell JJ; Waldron J; Xia P; Chung CH; Truong MT; Echevarria M; Chan JW; Geiger JL; Mell L; Seaward S; Thorstad WL; Beitler JJ; Sultanem K; Blakaj D; Le QT
    J Nucl Med; 2023 Mar; 64(3):362-367. PubMed ID: 36215572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Rosen BS; Wilkie JR; Sun Y; Ibrahim M; Casper KA; Miller JE; Chotchutipan T; Stucken CL; Bradford C; Prince MEP; Rosko AJ; Malloy KM; McLean SA; Chinn SB; Shuman AG; Spector ME; Swiecicki PL; Worden FP; Shah JL; Schonewolf CA; Chapman CH; Eisbruch A; Mierzwa ML
    Radiother Oncol; 2021 Feb; 155():174-181. PubMed ID: 33069764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
    Yom SS; Torres-Saavedra P; Caudell JJ; Waldron JN; Gillison ML; Xia P; Truong MT; Kong C; Jordan R; Subramaniam RM; Yao M; Chung CH; Geiger JL; Chan JW; O'Sullivan B; Blakaj DM; Mell LK; Thorstad WL; Jones CU; Banerjee RN; Lominska C; Le QT
    J Clin Oncol; 2021 Mar; 39(9):956-965. PubMed ID: 33507809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence.
    Sivarajah S; Isaac A; Cooper T; Zhang H; Puttagunta L; Abele J; Biron V; Harris J; Seikaly H; O' Connell DA
    JAMA Otolaryngol Head Neck Surg; 2018 Nov; 144(11):1037-1043. PubMed ID: 30242338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
    Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
    Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning.
    Chen TM; Chen WM; Chen M; Shia BC; Wu SY
    J Otolaryngol Head Neck Surg; 2023 Feb; 52(1):14. PubMed ID: 36782296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Diffusion-Weighted Imaging and
    Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
    Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
    Chen H; Li Y; Wu H; Sun L; Lin Q; Zhao L; An H
    Strahlenther Onkol; 2015 Feb; 191(2):141-52. PubMed ID: 25163419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes.
    Marcus C; Ciarallo A; Tahari AK; Mena E; Koch W; Wahl RL; Kiess AP; Kang H; Subramaniam RM
    J Nucl Med; 2014 Sep; 55(9):1411-6. PubMed ID: 24947059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (18)F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma.
    Bird T; Barrington S; Thavaraj S; Jeannon JP; Lyons A; Oakley R; Simo R; Lei M; Guerrero Urbano T
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1239-47. PubMed ID: 26707387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features.
    Wray R; Sheikhbahaei S; Marcus C; Zan E; Ferraro R; Rahmim A; Subramaniam RM
    AJR Am J Roentgenol; 2016 Sep; 207(3):641-7. PubMed ID: 27341273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma.
    Chan JY; Sanguineti G; Richmon JD; Marur S; Gourin CG; Koch W; Chung CH; Quon H; Bishop JA; Aygun N; Agrawal N
    Arch Otolaryngol Head Neck Surg; 2012 Nov; 138(11):1040-6. PubMed ID: 23165378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of quantitative (18)F-FDG-PET-CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma.
    Schouten CS; Hakim S; Boellaard R; Bloemena E; Doornaert PA; Witte BI; Braakhuis BJ; Brakenhoff RH; Leemans CR; Hoekstra OS; de Bree R
    Head Neck; 2016 Apr; 38(4):529-35. PubMed ID: 25352335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced MRI, diffusion-weighted MRI and
    Ng SH; Liao CT; Lin CY; Chan SC; Lin YC; Yen TC; Chang JT; Ko SF; Fan KH; Wang HM; Yang LY; Wang JJ
    Eur Radiol; 2016 Nov; 26(11):4162-4172. PubMed ID: 26911889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
    Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study.
    Van den Wyngaert T; Helsen N; Carp L; Hakim S; Martens MJ; Hutsebaut I; Debruyne PR; Maes ALM; van Dinther J; Van Laer CG; Hoekstra OS; De Bree R; Meersschout SAE; Lenssen O; Vermorken JB; Van den Weyngaert D; Stroobants S;
    J Clin Oncol; 2017 Oct; 35(30):3458-3464. PubMed ID: 28854069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-treatment 18F-FDG-PET/CT versus contrast-enhanced CT in patients with oropharyngeal squamous cell carcinoma: comparative effectiveness study.
    Taghipour M; Mena E; Kruse MJ; Sheikhbahaei S; Subramaniam RM
    Nucl Med Commun; 2017 Mar; 38(3):250-258. PubMed ID: 28099264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of combined assessments of 4D volumetric perfusion CT, diffusion-weighted MRI and
    Tsuchiya H; Matoba M; Nishino Y; Ota K; Doai M; Nagata H; Tuji H
    Radiat Oncol; 2023 Feb; 18(1):24. PubMed ID: 36747228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Earlier and more specific detection of persistent neck disease with diffusion-weighted MRI versus subsequent PET/CT after definitive chemoradiation for oropharyngeal squamous cell carcinoma.
    Yu Y; Mabray M; Silveira W; Shen PY; Ryan WR; Uzelac A; Yom SS
    Head Neck; 2017 Mar; 39(3):432-438. PubMed ID: 27726241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.